The total return over the past 12 months is +21.86% vs. +16.94% for the S&P 500. So far it's up -20.10% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +21.86% | +8.04% | (26.94%) | (7.11%) | N/A | N/A |
| Total Return CAGR | +21.86% | +8.04% | (26.94%) | (7.11%) | N/A | N/A |
| Revenue CAGR | +0.70% | (6.79%) | (7.65%) | (3.15%) | +7.28% | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Enanta Pharmaceuticals, Inc. (ENTA)
| Year | Start price | End price | ENTA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $15.77 | $12.60 | (20.10%) | +14.51% | (34.61%) |
| 2025 | $5.75 | $15.77 | +174.26% | +17.72% | +156.54% |
| 2024 | $9.41 | $5.75 | (38.89%) | +24.89% | (63.78%) |
| 2023 | $46.52 | $9.41 | (79.77%) | +26.19% | (105.96%) |
| 2022 | $74.78 | $46.52 | (37.79%) | (18.17%) | (19.62%) |
| 2021 | $42.10 | $74.78 | +77.62% | +28.74% | +48.88% |
| 2020 | $61.78 | $42.10 | (31.85%) | +18.37% | (50.22%) |
| 2019 | $70.83 | $61.78 | (12.78%) | +31.22% | (44.00%) |
| 2018 | $58.68 | $70.83 | +20.71% | (4.56%) | +25.27% |
| 2017 | $33.50 | $58.68 | +75.16% | +21.70% | +53.46% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
